Fate Therapeutics reports Q3 2026 net loss of $30.7 million, down from $32.3 million
Fate Therapeutics reported third quarter 2026 results with a net loss of $30.7 million, or $(0.25) per share, compared with $32.3 million, or $(0.27) per share, a year earlier. Collaboration revenue was zero in the quarter, down from $1.7 million, and cash, cash equivalents, and investments totaled $139.1 million, which the company says extends its cash runway to mid-2028.
Key points
- Net loss was $30.7 million, or $(0.25) per share, versus $32.3 million, or $(0.27) per share, in Q3 2025.
- Collaboration revenue was $0 in Q3 2026, compared with $1.7 million in Q3 2025.
- Total operating expenses were $32.2 million, down from $36.5 million a year earlier.
- Cash and investments were $139.1 million at September 30, 2026, excluding a $15.0 million CIRM grant award.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.